MARKET WIREYahoo Finance • 10h ago
Why Medifast (MED) stock is trading up todayYahoo Finance report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
Why MED Stock slipped -0.90% Today — RQD Quant Desk Flash
$12.15 -0.90% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot)
EXT / AFTER-HRS: $12.11
MEDIFAST INC (MED) carries a Roarable Rating of D (Sell) with 50/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.
ROARABLE D • SELL / AVOID
Cap $137.1M
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER
Click Any Pre-Computed AI Quant Specialist Briefing on MED Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief)
Is MED stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼
As of 2026-11-02, MEDIFAST INC (NYSE: MED) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $12.15 (-0.90% 1D, market cap $137.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 146 tracked Consumer Staples issuers, MED ranks #78 in composite RQD confidence.
✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief)
How does MED compare to BYND and BGS in the Consumer Staples sector?
▼
Within the Consumer Staples sector (Packaged Foods), MED carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 71.3%, and ROIC of -10.2%. By comparison, BYND (Beyond Meat Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $126.9M) and BGS (B&G Foods Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC 3.3%, cap $183.7M). Among the 5-stock peer group, MED leads on earnings multiple (N/A) while BGS leads on capital efficiency (3.3% ROIC).
✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief)
What are the biggest fundamental strengths and SEC risk factors for MED?
▼
Per MED's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000910329), MEDIFAST INC generated $385.8M in revenue (-36.0% YoY), -$19.0M in net income, and $1.2M in free cash flow against $248.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
EXT / AFTER-HRS: $12.11 (-0.35%)🧬 Dilution Drag (+1.92% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 0.3% FCF Margin
Verify 90D Bucket Audit →📊 Historical Track Record: Scores of 50/100 (D) historically posted market-perform odds over rolling 90-day windows (-1.4% avg 90D alpha vs SPY • 49.3% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →RQD QUANT TACHOMETERSELL / AVOID • D
JEV AI Jury Split (Battleground)
Cash
SEC
Whale
Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer
5-PILLAR SNOWFLAKE RADARRw D · Rk D+
Each axis scored 0–20
12M PRICE TARGET CONE-3.6% Base Target
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for MED)Realized 20D OHLCV Swing Band: ±7%
Deterministic 5-Pillar Attribution (50/100 Composite)
🔍 WHY MED SCORES 50/100 (D) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: Cash Engine Quality+12/20 pts (24% of score)
SEC XBRL FY 2025 (10-K): 0.3% FCF Margin ($1.2M FCF) & 71.3% Gross Margin
▲ #2 Bullish Driver: Whale & Options Positioning+12/20 pts (24% of score)
20D Institutional Volume Accumulation (±7% realized swing band)
▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution5/20 pts (-15 pt drag)
Dilution Drag (+1.92% YoY Shares) & executive Form 4 sales trim 15 pts from alignment
📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)Grade D$11.62+3.5% Next Q
42
Q2 (-2Q)Grade D$12.03+0.7% Next Q
45
Q3 (-1Q)Grade D$12.11+0.3% Next Q
47
CurrentGrade D$12.15-1.4% Hist 90D α
50
Trajectory: D (42) → D (50)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER
⚔️ Adversarial Opposing Case: What Could Spark a MED Turnaround Squeeze
While MED currently carries a cautious 50/100 (D) rating due to Insider Conviction & Share Dilution (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.
🚀 Contrarian Squeeze Trigger #1
Established market leader in Consumer Staples with deep daily trading liquidity.
🚀 Contrarian Squeeze Trigger #2
Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($12.00) and Max Pain ($12.76) forces dealer call-delta covering toward $14.12.
🚀 Contrarian Squeeze Trigger #3
Forensic Repair Trigger: Halting share dilution (Dilution Drag (+1.92% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.
🎲 LIVE PREDICTION MARKET ODDS TIED TO $MED• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “MED Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
AUTOMATED RQD QUANT DESK MOVER BRIEFINGFull Market News Desk →
Why MED Stock slipped -0.90% Today — RQD Quant Desk Flash
MEDIFAST INC (MED) slipped -0.90% to $12.15, trading at 69% of its 52-week range ($9.22 – $13.45). Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.
- ▸Technical Tape: Trading at 69% of its 52-week range ($9.22 – $13.45) with RSI-14 at 56.7 (BULLISH MOMENTUM).
- ▸Volatility Profile: Historical 20-day realized swing band of ±7% around $12.15 (no active unusual options sweep snapshot on file).
- ▸Fundamental Anchor: Roarable D (Sell) backed by 71.3% gross margin and $1.2M annual free cash flow.
Live MED Headlines & Catalysts
MARKET WIRETradingView • 13h ago
Can Medifast's Better Client Retention Support Revenue Stabilization?TradingView report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
MARKET WIRESeeking Alpha • 16h ago
Medifast Is Running The Same Playbook, And I Have The Same Concerns (NYSE:MED)Seeking Alpha report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
RISK WATCHYahoo Finance • 19h ago
Medifast (MED) Reports Q3 Loss, Tops Revenue EstimatesYahoo Finance report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
MARKET WIREMarketBeat • 22h ago
Medifast (MED) Expected to Release Quarterly Earnings on MondayMarketBeat report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
MARKET WIREStock Titan • 1d ago
The number of coaches actively earning at Medifast fell 47.7%, to 10,200.Stock Titan report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
MARKET WIREThe Globe and Mail • 1d ago
1 Small-Cap Stock with Impressive Fundamentals and 2 Facing ChallengesThe Globe and Mail report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
RISK WATCHSimply Wall St • 1d ago
Medifast (MED) Q3 Results Deepen Losses As Coach Count ShrinksSimply Wall St report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
MARKET WIREYahoo • 5d ago
MED Q3 deep dive: new Trilogy brand and coach productivity drive evolving metabolic health strategyWellness company Medifast (NYSE:MED) reported Q3 2026 results topping the market’s revenue expectations, but sales fell by 19.4% year on year to $72.05 million. Guidance for next quarter’s revenue was better than expecte
MARKET WIREYahoo • 5d ago
5 insightful analyst questions from Medifast’s Q3 earnings callMedifast’s third quarter results were marked by a positive market response, as the company’s revenue slightly exceeded Wall Street’s expectations despite a substantial year-over-year decline. Management attributed the pe
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk
Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring MED)
- ✓Walkthrough of MED's RQD Radar, SEC cash-conversion gap & downside invalidation levels
- ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
- ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
MED // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +14.30%📐 HORIZONTAL RANGE
2026-11-02O $12.28H $12.28L $12.15C $12.15VOL 124.5K
RES: $13.46SUP: $11.33SMA50: $12.00SMA200: $11.32
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK
MED Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure
Share Count & Dilution Monitor (#25)
Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).
Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth
vs. -36.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).
Ellis Vennor Setup Ledger (#33)
No active Ellis Vennor swing setup published on MED today. View full Setup Ledger →
🦋 Documented & Second-Order Butterfly Connections
Open Graph →
No direct multi-tier Butterfly edges indexed yet for MED. Explore sector supply chains on /butterfly.
AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for MED today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK
📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (MED)
Consumer Staples Rank #78 of 146
⚔️ BYND vs MED Full Matrix →
1. Head-to-Head Consumer Staples Peer Comparison (MED vs. BYND, BGS, OTLY, AFRI)
Industry: Packaged Foods (41 Tracked Issuers)Across 146 tracked Consumer Staples securities in the Roarable RQD universe, MEDIFAST INC (MED) ranks #78 by composite RQD confidence (50/100, grade D) and #99 by equity capitalization ($137.1M). Within this direct 5-issuer industry benchmark cohort, MED leads on earnings valuation at N/A trailing P/E, while BGS leads on capital efficiency and profitability with 3.3% ROIC and 21.8% gross margin. MED currently leads its immediate peer cohort in composite quantitative strength at 50/100 (D).
| Ticker / Company | Roarable Grade | RQD Score | Trailing P/E | Gross Margin | ROIC | 1D Change | Market Cap | Head-to-Head |
|---|---|---|---|---|---|---|---|---|
| MED
ACTIVE
MEDIFAST INC | D | 50/100 | — | 71.3% | -10.2% | -0.90% | $137.1M | Benchmark Subject |
| BYND Beyond Meat Inc. | E | 29/100 | — | — | -35.0% | -6.37% | $126.9M | /bynd-vs-med → |
| BGS B&G Foods Inc. | E | 28/100 | — | 21.8% | 3.3% | +2.66% | $183.7M | /bgs-vs-med → |
| OTLY Oatly Group AB | D | 45/100 | — | — | — | -3.12% | $255.3M | /otly-vs-med → |
| AFRI Forafric Global PLC | E | 24/100 | — | 10.4% | -16.5% | -0.95% | $340.6M | /afri-vs-med → |
2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)
SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0000910329In its most recent audited fiscal period (FY2025, filed 2025-12-31), MEDIFAST INC (MED) reported GAAP revenue of $385.8M (-36.0% vs. FY2024 revenue of $602.5M , and -64.0% cumulative change since FY2023) , GAAP net income of -$19.0M, operating cash flow of $6.9M, and free cash flow of $1.2M (-92.7% YoY). On the balance sheet, MED closed FY2025 with $248.0M in total assets against $0 in total debt (Altman Z-Score: 4.71, Piotroski F-Score: 5/9).
| Fiscal Period | Filing Date | Revenue | Net Income | Operating Cash Flow | Free Cash Flow | Total Assets | Total Debt |
|---|---|---|---|---|---|---|---|
| FY2025 (FY) | 2025-12-31 | $385.8M | -$19.0M | $6.9M | $1.2M | $248.0M | — |
| FY2024 (FY) | 2024-12-31 | $602.5M | $2.0M | $24.5M | $17.0M | $284.2M | — |
| FY2023 (FY) | 2023-12-31 | $1.07B | $99.0M | $147.7M | $147.7M | — | — |
3. MED Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)
✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLEDIs MED stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
As of 2026-11-02, MEDIFAST INC (NYSE: MED) is rated D (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 50/100 at a spot price of $12.15 (-0.90% 1D, market cap $137.1M). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 12/20, Executive Insider Alignment 11/20, FRED Macro Regime Fit 10/20, and SEC Balance-Sheet Forensics 5/20. Across 146 tracked Consumer Staples issuers, MED ranks #78 in composite RQD confidence.
How does MED compare to BYND and BGS in the Consumer Staples sector?
Within the Consumer Staples sector (Packaged Foods), MED carries a Roarable D (50/100 RQD), trailing P/E of N/A, gross margin of 71.3%, and ROIC of -10.2%. By comparison, BYND (Beyond Meat Inc.) holds a E grade (29/100 RQD, P/E N/A, ROIC -35.0%, cap $126.9M) and BGS (B&G Foods Inc.) posts a E grade (28/100 RQD, P/E N/A, ROIC 3.3%, cap $183.7M). Among the 5-stock peer group, MED leads on earnings multiple (N/A) while BGS leads on capital efficiency (3.3% ROIC).
What are the biggest fundamental strengths and SEC risk factors for MED?
Per MED's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0000910329), MEDIFAST INC generated $385.8M in revenue (-36.0% YoY), -$19.0M in net income, and $1.2M in free cash flow against $248.0M in total assets and $0 in total debt. Key quantitative strengths: Established market leader in Consumer Staples with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.
Where is MED trading relative to its 50-day, 200-day, and 52-week technical levels?
MED last traded at $12.15 (-0.90% on volume of 231,919 shares), positioning the stock +1.25% above its 50-day simple moving average ($12.00) and +7.33% above its 200-day simple moving average ($11.32). Across its 52-week range of $9.22 to $13.45, MED sits at the 69.3% percentile with a 14-day RSI of 56.7 (BULLISH MOMENTUM) and an implied next-earnings move of ±7.0% ($11.30 to $13.00).
MED Investor FAQ & Complete 8-Part Research Index
100% OPEN ACCESS • SEC EDGAR × CBOE × FREDWhy is MED stock moving today?
Why MED Stock slipped -0.90% Today — RQD Quant Desk Flash. Stretched risk/reward at current multiples (-10% return on capital) under elevated 10-year interest-rate pressure.
ROARABLE RATING BRIEF • RQD 50/100 (D)
✓ STAGE-C NUMBER FIREWALL VERIFIED
MED — MEDIFAST INC: What the Facts Mean to a Prospective Investor
Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T15:42:54Z
Roarable Rating Brief: What This Means to a Prospective Investor
Per the Roarable RQD rating, MED scores 50 out of 100 for a letter grade of D, with the verdict label "Roarable Sell — Underperform / Distribution Warning." The five pillars are:
- Fundamental Cash Engine: 12 / 20. Per the Roarable RQD rating, this pillar reflects ROIC of -10.2% and an FCF yield of 0.91%. Negative return on invested capital means the business is currently not earning back its capital base, and a sub-1% FCF yield indicates limited free cash generation relative to the market value.
- Whale / 13F Flow: 12 / 20. Per the Roarable RQD rating, the pillar reflects institutional accumulation and options positioning. No holder-level detail is included in the source data, so the drivers of this score cannot be independently traced here.
- Insider Conviction: 5 / 20. Per the Roarable RQD rating, this is the weakest pillar and reflects SEC Form 4 and Congressional PTR cluster flow. The low score signals weak insider-side conviction; the underlying trade-level records are not included in the source data.
- Macro Regime Fit: 10 / 20. Per the Roarable RQD rating, the pillar cites a beta of 1.0 and sector sensitivity. A beta of 1.0 implies market-level sensitivity to broad moves, without a defensive or aggressive tilt.
- Forensic Balance Sheet: 11 / 20. Per the Roarable RQD rating, the pillar reflects Altman Z 4.71, Piotroski F 5/9, and Debt/Equity 0.5. These metrics point to a balance sheet that is more stable than the earnings trajectory alone would suggest.
For a prospective investor evaluating the stock today, the composite picture is one of weak profitability and cash generation offset in part by a relatively sound balance-sheet profile. The upside drivers the data supports are the forensic balance sheet and the institutional-flow pillar; the headwinds are negative ROIC, a thin FCF yield, and weak insider conviction. Valuation tradeoffs cannot be assessed precisely because P/E and EV/EBITDA are not available in source data. The rating is a descriptive summary of the data provided and is not a recommendation.
Financial Trend
| Period | Revenue | Operating Income | Net Income | EPS | FCF | Cash | Debt |
|---|---|---|---|---|---|---|---|
| FY 2025 | $385.8M | $-14.2M | $-19.0M | N/A | $1.2M | $89.3M | N/A |
| FY 2024 | $602.5M | $2.9M | $2.0M | N/A | $17.0M | $90.9M | N/A |
| FY 2023 | $1072.1M | $126.4M | $99.0M | N/A | $147.7M | N/A | N/A |
Per the SEC financials, revenue declined from $1072.1M in FY 2023 to $385.8M in FY 2025, and the company moved from positive operating income in FY 2023 and FY 2024 to an operating loss of $-14.2M in FY 2025. Per the market data, operating margin is -3.7%, net margin is -4.9%, and ROIC is -10.2%. Per the Roarable RQD rating, the Altman Z-Score is 4.71 and the Piotroski F-Score is 5/9, and Debt/Equity is 0.5. Reported cash was $89.3M at FY 2025. Debt is not available in source data for any period.
Recent Catalysts & News Wire Analysis
Per the recent news and catalysts feed, six items relate to MED:
- An item labeled "Why Medifast (MED) stock is trading up today" from Yahoo Finance (YELLOW, MARKET WIRE).
- An item on whether Medifast's client retention can support revenue stabilization from TradingView (YELLOW, MARKET WIRE).
- A Seeking Alpha item expressing concerns about the company's playbook (YELLOW, MARKET WIRE).
- A Yahoo Finance item reporting a Q3 loss while topping revenue estimates (RED, RISK WATCH).
- A MarketBeat item noting an expected quarterly earnings release on Monday (YELLOW, MARKET WIRE).
- A Stock Titan item reporting the number of actively earning coaches fell 47.7% to 10,200 (YELLOW, MARKET WIRE).
The only item flagged RISK WATCH is the Q3 loss report. The butterfly supply-chain graph contains no links and no proprietary signals.
Butterfly Effect: 2nd-Order Supply-Chain & Sector Ripples
Per the Butterfly Supply-Chain Graph, supply chain is listed as NONE, with no butterfly links and no proprietary signals. Upstream and downstream dependencies, sector correlations, and second-order bottlenecks cannot be mapped from the source data. The only sector context available is the classification as Consumer Staples / Packaged Foods. An investor should watch for the coach-count decline and client-retention commentary in the news feed as potential indicators of demand conditions, but the source data does not establish any linkage to other companies.
Open Questions
- What are the company's P/E (TTM), forward P/E, and EV/EBITDA, and how do they compare with peers?
- What drove the revenue decline from $1072.1M in FY 2023 to $385.8M in FY 2025, and is the trend continuing into the current period?
- What is the company's debt position by period, given that debt is listed as N/A throughout the financials?
- What are the specific insider and institutional trades behind the Insider Conviction and Whale/13F Flow pillar scores?
- What did the Q3 loss report disclose about operating drivers, and what does the FY 2025 cash balance imply about funding runway?
MED Live News Feed, Press Releases & Catalyst Wire
Real-time company headlines, analyst actions, and sector developments for MEDIFAST INC (MED) • Click "Debate This Headline" to argue it in the Roar Pit below
🟡 MARKET WIRE Yahoo Finance • 10h ago
Why Medifast (MED) stock is trading up today Yahoo Finance report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE TradingView • 13h ago
Can Medifast's Better Client Retention Support Revenue Stabilization? TradingView report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Seeking Alpha • 16h ago
Medifast Is Running The Same Playbook, And I Have The Same Concerns (NYSE:MED) Seeking Alpha report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Yahoo Finance • 19h ago
Medifast (MED) Reports Q3 Loss, Tops Revenue Estimates Yahoo Finance report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE MarketBeat • 22h ago
Medifast (MED) Expected to Release Quarterly Earnings on Monday MarketBeat report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE Stock Titan • 1d ago
The number of coaches actively earning at Medifast fell 47.7%, to 10,200. Stock Titan report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
🟡 MARKET WIRE The Globe and Mail • 1d ago
1 Small-Cap Stock with Impressive Fundamentals and 2 Facing Challenges The Globe and Mail report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
🔴 RISK WATCH Simply Wall St • 1d ago
Medifast (MED) Q3 Results Deepen Losses As Coach Count Shrinks Simply Wall St report covering MEDIFAST INC (MED) market action, institutional positioning, and fundamental catalysts.
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE
3 Active Posts & Replies
MED Bull vs. Bear Conversation Board — What's Your Call at $12.15?
🐂 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON MED 🐻 50% BEARISH CONVICTION
RO RoarDesk_Moderator Roarable Research Desk ⚖️ DEBATE HOST
🎯 Target: $13.24 (+8.0%)
📌 Pinned Debate 🔥 Official Bull vs. Bear Debate: Is MED (D • RQD 50/100) a Buy at $12.26?
Welcome to the MED (MEDIFAST INC) Roar Pit. Current RQD Composite is 50/100 (Roarable Sell — Underperform / Distribution Warning) in Packaged Foods. Bulls point to operating leverage and sector positioning, while bears focus on macro rate sensitivity and margin execution. Pick your side (🐂 Bull or 🐻 Bear) and drop your price target below.
FO ForensicBear Forensic Accounting Watch 🐻 BEARISH
🎯 Target: $9.44 (-23.0%)
Spot @ $12.26 Pump the brakes on MED — check the valuation vs. margin headwinds
Everyone in here is repeating the bull case on MED, but look at what you are paying: current EV/EBITDA multiples with 71.3% gross margins. Unless MEDIFAST INC expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.
TA TapeReader_Pro Verified K Arena Trader 🐂 BULLISH
🎯 Target: $14.22 (+16.0%)
Spot @ $12.26 MED cash flow & RQD setup is being underpriced by the Street here
Looking at the 5-pillar RQD breakdown on MED, the market is fixating on short-term headline noise in Packaged Foods and ignoring the balance sheet and cash flow trajectory. At $12.26 (52-wk range $9.22 - $13.45), any beat on forward guidance forces shorts and underweight funds to chase.